KLRSKalaris Therapeutics Inc. Common Stock
4.150USD-0.48%Mkt Cap: 98.79M $P/E: —3d ago
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular end…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board Kalaris Therapeutics, Inc. (NASDAQ:KLRS) is one of the 10 High Growth Stocks Insiders Are Buying. On July 6, 2026, Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In connection with Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board. David Hallal, Chairman of […] | IInsider Monkey | |